CancerDrs

Lung Cancer clinical trials

300 actively recruiting lung cancer trials in the United States. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Trials focus on targeted therapies, immunotherapy, and combination regimens.

Data from ClinicalTrials.gov · last refreshed · Lung Cancer stats on SEER

65
Phase 1
96
Phase 2
38
Phase 3
1
Phase 4
100
Other

Lung Cancer by the numbers (U.S.)

226,650
Estimated new cases (2025)
124,730
Estimated deaths (2025)
28.1%
5-year relative survival
71
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse lung cancer trials by state

Texas 122 California 112 New York 92 Florida 81 Virginia 73 Ohio 71 Tennessee 70 Michigan 68 Massachusetts 67 Pennsylvania 66 Maryland 59 New Jersey 56 Washington 54 Illinois 53 Missouri 49 Georgia 48 Colorado 46 North Carolina 45 Minnesota 43 Arizona 41 Oregon 40 Kentucky 36 Wisconsin 33 District of Columbia 30 Connecticut 29 Nebraska 28 South Carolina 28 Utah 27 Indiana 25 Oklahoma 25 Arkansas 23 Kansas 23 South Dakota 22 Alabama 21 Nevada 21 Iowa 19 Delaware 17 Louisiana 16 Maine 16 New Hampshire 16 Mississippi 15 Montana 15 Rhode Island 15 West Virginia 14 North Dakota 13 Idaho 12 New Mexico 12 Hawaii 9 Vermont 9 Alaska 8 Wyoming 3

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Locations:
  • Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama

+ 1198 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama

+ 467 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Katmai Oncology Group — Anchorage, Alaska
  • Cancer Center at Saint Joseph's — Phoenix, Arizona

+ 412 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Network

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Locations:
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama

+ 383 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona

+ 374 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Locations:
  • Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • Highlands Oncology Group - Rogers — Rogers, Arkansas

+ 315 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas

+ 253 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Locations:
  • Local Institution - 007-556-A — Goodyear, Arizona
  • USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
  • Local Institution - 007-568-A — Safford, Arizona

+ 217 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Locations:
  • Pioneer Research Center — Bullhead City, Arizona
  • Ironwood Cancer & Research Centers — Chandler, Arizona
  • Ironwood Cancer & Research Centers — Gilbert, Arizona

+ 148 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…

Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Locations:
  • Clinical Research Advisors, LLC — Beverly Hills, California
  • Clinical Research Advisors - Encino — Encino, California
  • Clinical Research Advisors - West Hollywood — Los Angeles, California

+ 76 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Locations:
  • Clearview Cancer Institute — Huntsville, Alabama
  • Infirmary Cancer Care — Mobile, Alabama
  • The University of Arizona Cancer Center - North Campus — Tucson, Arizona

+ 75 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC …

Sponsor: AstraZeneca
NCT ID: NCT06627647
Locations:
  • Research Site — Mobile, Alabama
  • Research Site — Chandler, Arizona
  • Research Site — Phoenix, Arizona

+ 74 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

How to read clinical trial eligibility →

Inclusion, exclusion, biomarker requirements, performance status, and prior-therapy rules.

 How to find a clinical trial →

Search strategy, matching services, and when to involve your oncologist.

 Clinical trial phases explained →

Phase 1 through 4, what each means for patients.

 Insurance coverage for clinical trials →

The ACA requires coverage of routine patient costs. How to appeal denials.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-11